» Articles » PMID: 34677095

Health Profile of Preterm Males With Duchenne Muscular Dystrophy

Overview
Journal J Child Neurol
Specialties Neurology
Pediatrics
Date 2021 Oct 22
PMID 34677095
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

In this retrospective cohort study, we characterize the health profile of preterm males with Duchenne muscular dystrophy. Major clinical milestones (ambulation cessation, assisted ventilation use, and onset of left ventricular dysfunction) and corticosteroids use in males with Duchenne muscular dystrophy identified through a population-based surveillance system were analyzed using Kaplan-Meier survival curves and Cox proportional hazards modeling. The adjusted risk of receiving any respiratory intervention among preterm males with Duchenne muscular dystrophy was 87% higher than among the corresponding full-term males with Duchenne muscular dystrophy. The adjusted risks for ambulation cessation and left ventricular dysfunction were modestly elevated among preterm compared to full-term males, but the 95% confidence intervals contained the null. No difference in the start of corticosteroid use between preterm and full-term Duchenne muscular dystrophy males was observed. Overall, the disease course seems to be similar between preterm and full-term males with Duchenne muscular dystrophy; however, pulmonary function seems to be affected earlier among preterm males with Duchenne muscular dystrophy.

Citing Articles

Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec.

Asher D, Dai D, Klimchak A, Sedita L, Gooch K, Rodino-Klapac L Mol Ther Methods Clin Dev. 2023; 30:474-483.

PMID: 37674905 PMC: 10477757. DOI: 10.1016/j.omtm.2023.08.002.


Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States.

Klimchak A, Sedita L, Rodino-Klapac L, Mendell J, McDonald C, Gooch K J Mark Access Health Policy. 2023; 11(1):2216518.

PMID: 37261034 PMC: 10228300. DOI: 10.1080/20016689.2023.2216518.

References
1.
Connuck D, Sleeper L, Colan S, Cox G, Towbin J, Lowe A . Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2008; 155(6):998-1005. PMC: 2729548. DOI: 10.1016/j.ahj.2008.01.018. View

2.
Gloss D, Moxley 3rd R, Ashwal S, Oskoui M . Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016; 86(5):465-72. PMC: 4773944. DOI: 10.1212/WNL.0000000000002337. View

3.
McNally E . New approaches in the therapy of cardiomyopathy in muscular dystrophy. Annu Rev Med. 2007; 58:75-88. DOI: 10.1146/annurev.med.58.011706.144703. View

4.
Luu T, Katz S, Leeson P, Thebaud B, Nuyt A . Preterm birth: risk factor for early-onset chronic diseases. CMAJ. 2015; 188(10):736-746. PMC: 4938684. DOI: 10.1503/cmaj.150450. View

5.
Cyrulnik S, Fee R, De Vivo D, Goldstein E, Hinton V . Delayed developmental language milestones in children with Duchenne's muscular dystrophy. J Pediatr. 2007; 150(5):474-8. PMC: 1931426. DOI: 10.1016/j.jpeds.2006.12.045. View